Navigation Links
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Date:3/13/2013

a collaboration partner to help fund clinical development and, if approved, commercialization.

Conference Call Today at 5 p.m. Eastern Time (2:00 p.m. Pacific Time)
The Orexigen management team will host a teleconference and webcast to discuss the fourth quarter and full year 2012 financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 34404715. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward-Looking Statements
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the timing of the interim analysis and resubmission of the  Contrave NDA, the  ra
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... marketplace, innovative consumer research and marketing communication tools ... rich and globally competitive – consequently consumers, desires, ... In this environment, market research groups across ... research and marketing communication tools. However, the adoption ...
(Date:12/19/2014)... 18, 2014 Research and Markets ... the "Micro Market Monitor: North American Dermatology ... http://photos.prnewswire.com/prnh/20130307/600769 ... steadily, which has resulted in fueling the overall ... main purpose of these dermatology devices is to ...
(Date:12/19/2014)... Dec. 18, 2014 Baptist Health Lexington is the ... to receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation ... Atrial fibrillation is the most common cardiac arrhythmia and ... cases can lead to stroke and possible death. More than ... have atrial fibrillation and the numbers are rapidly increasing ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... SEATTLE, May 30, 2012  Aequus BioPharma, Inc. ("Aequus"), a ... and MTA: CTIC), announced today that its GlycoPolymer technology ... AQB-101 drug candidate, was selected for an oral presentation ... The meeting will be held on May 28-30, 2012, ...
... Medical Center (DMC) and Henry Ford Health System (HFHS) ... renewal and bring jobs to the city of Detroit. ... As part of the economic recovery effort, DMC and ... Health, enabling the company to relocate a medical products ...
Cached Medicine Technology:Cell Therapeutics' Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs 2Cell Therapeutics' Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs 3Cell Therapeutics' Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs 4Cardinal Health, Detroit Medical Center, Henry Ford Health System Announce Unique Collaboration To Promote Urban Renewal 2Cardinal Health, Detroit Medical Center, Henry Ford Health System Announce Unique Collaboration To Promote Urban Renewal 3Cardinal Health, Detroit Medical Center, Henry Ford Health System Announce Unique Collaboration To Promote Urban Renewal 4
(Date:12/22/2014)... At the annual National League ... San Antonio, esteemed experts and thought leaders will ... in the way of successful organizational performance: resistance, ... faculty development opportunity is made possible through the ... to assist nurse educators to advance to leadership ...
(Date:12/21/2014)... 2014 Weddingshe.com, an outstanding online supplier ... recently released its new selection of Cocktail Dresses for ... according to the newest fashion trends. , ... for cocktail parties . All of them are offered ... We are making every effort to offer a nice ...
(Date:12/21/2014)... new collection of 2015 spring wedding dresses was released ... in this collection, and all of them are designed ... promises to provide the most fashionable designs to its ... trends come and go. If ladies have any questions ... ready to assist. , “These new models can ...
(Date:12/21/2014)... The number of Mirena lawsuits ( ... underway in New Jersey, Bernstein Liebhard LLP reports. , ... involving the birth control IUD have now been filed ... by women who allege spontaneous migration of the device, ... and other complications they were inadequately warned about by ...
(Date:12/21/2014)... Over the past 39 years, NES Health ... emergency departments across the nation, from quality of medical ... into an innovative suite of tools, systems, and programs ... the patient experience. , NES Health, a leading ... services for hospitals, announced the development and launch of ...
Breaking Medicine News(10 mins):Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2
... May 18 ... USNA ) launched a nationwide geocaching event ... Energy (TM). Rev3 is a tea-based beverage, containing antioxidants ... lift. To view the Multimedia News Release, go to: ...
... -- ACORN CRO, an oncology-focused CRO, has developed ... The introduction of this dedicated technology tool will speed ... feasibility process. "STAR was developed under the guidance of ... valuable time during the study start-up phase. The resulting ...
... 18 Bell Environmental Services (BES) , a ... area, is offering a travel bed bug kit to ... this summer, business travelers and anyone traveling away from ... Bed Bug Kit contains a 6 ounce bed ...
... May 18 AtlantaNAP ( www.atlantanap.com ... client, Health Information Designs.As a strategic initiative to consolidate ... a need for a true Tier III facility, Health ... data center facility for its core operations. The ...
... and Washinton DC (18 May 2009) Research published this ... estimate the annual costs of autism spectrum disorder (ASD) to ... supporting children with ASDs were estimated to be 2.7 billion ... will be presented at the Autism & Employment Workshop taking ...
... Product to Shift Employees to HSA Plans and Cut CostsAMHERST, ... low-cost, customizable platform for employee HSA education. StreetWise HSA ... transition their employees to Health Savings Account plans and cut ... platform that:, , ...
Cached Medicine News:Health News:Photos: USANA Launches National Rev3 Geocaching Challenge 2Health News:ACORN CRO Launches STAR (Site Tracking and Recruitment) 2Health News:Travel Bed Bug Kit Available for 2009 Summer Travel Season 2Health News:GNAX/AtlantaNAP Announces Newest Client, Health Information Designs 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 3Health News:StreetWise HSA(SM) Launched Nationally: First Low-Cost, Customizable Platform for Employee HSA Education 2
... CardioSEAL is a second generation device, ... was tested in over 700 patients beginning ... of leading pediatric cardiologists who perform these ... computer simulations, on the engineering bench, and ...
... YAG laser YC-1600 is a lightweight, compact, ... and clinical performance., ,Key Features, , ... Model ,Further weight reduction has been made ... office.,, Aiming Beam Rotation ,(360 degrees ...
... delivers a solid-state green laser ... and plugs into any standard ... and extreme portability, the unit ... Nidek Phaco Emulsification System CV-24000 ...
... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
Medicine Products: